Meningococcal serogroup B vaccine

This page covers all Meningococcal serogroup B vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Neisseria meningitidis serogroup B surface antigens.

Targets

Neisseria meningitidis serogroup B surface antigens

Marketed (1)

• rMenB+OMV NZ vaccine · GlaxoSmithKline · Immunology / Infectious Disease
  This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B by combining recombinant meningococcal protein antigens with outer membrane vesicles from a New Zealand strain.

Patent intelligence

• meningococcal serogroup b vaccine patent landscape — aggregated cliff calendar, attackable patents, originator estates